No Wrinkles in Actavis' $66 Billion Deal to Buy Botox Maker Allergan

---

Reported by Annette Kreuger for Industrial Info Resources (Sugar Land, Texas)--Pharmaceutical company Allergan (NYSE:AGN) (Irvine, California) has accepted a $66 billion buyout offer from Actavis (NYSE:ACT) (Dublin, Ireland), following months of pursuit by Valeant Pharmaceuticals (NYSE:VRX) (Laval, Quebec). Allergan, known chiefly for wrinkle reducer Botox, had continually spurned Valeant's offers, which had reached a peak of $53 billion last May.

See below for a list of Actavis and Allergan manufacturing plants & research sites in North America.

Actavis will spend $219 in cash and stock for each share of Allergan, considerably higher than the $179 for the same that Valeant offered. In addition to the popular Botox, Actavis is eager to add Allergan's promising experimental eye treatments for macular degeneration and glaucoma into its pipeline.

The Actavis deal was unanimously approved by Allergan's board, with Allergan Chairman and CEO David E.I. Pyott commenting: "We are combining with a partner that is ideally suited to realize the full potential inherent in our franchise."

The Allergan deal follows a spurt of recent Actavis buys. Earlier this year, the company scooped up Forest Laboratories for $28 billion, after acquiring Irish drugmaker Warner-Chilcott for $8.5 billion in 2013. The Warner-Chilcott purchase spurred a move of Actavis' headquarters from Parsippany, New Jersey, to Dublin, Ireland, in part to take advantage of enormous tax savings.

Once the deal makes it through the approval process, and the buy is complete, Actavis expects to make the list of the top 10 global pharmaceutical companies by sales revenue, with combined annual pro-forma revenues of more than $23 billion anticipated in 2015.

	Actavis/Allergan Manufacturing Plants & Research Sites in North America
Plant ID	Plant Name	State
3049856	North Brunswick Global R&D Technology Center	New Jersey
1519143	Vandalia Orally Disintegrating Tablets, Capsules & Sachets	Ohio
3108015	Fall River Levadex Inhalables	Massachusetts
1061591	Weston Generic Pharmaceutical Distribution	Florida
1063064	Mont Saint Hilaire Ointments, Oral Liquids & Solid Doses	Quebec
1518311	Santa Barbara Surgical Implant Device R&D	California
1062256	Corona Generic Solid Dose Tablets & Capsules	California
1062726	Salt Lake City Transdermals, Gels & Ointments OTC's	Utah
1080083	Campbell Botox Cosmetic Injectables	California
1063249	Commack Lexapro & Other Tablets/Teflaro Injectable	New York
3034456	Olive Branch Generic Pharma Distribution	Mississippi
1513200	Copiague Generic Nicotine Gums	New York
1012747	Irvine Sterile Injectables, Eye Drops & Cream Mid Stage R&D	California
1510460	Elizabeth Generic Oral Solid Doses, Tablets, Capsules	New Jersey
1030110	Manati Pharmaceutical Warehouse and Distribution	Puerto Rico
1061463	Fajardo Female Health Prods, Dermatology, Urology	Puerto Rico
1063220	Cincinnati Tablets, Capsules & Other Solid Doses and Liquids	Ohio
1063238	Farmingdale Pharmaceuticals R&D	New York
1001565	Waco Injectable Gels, Medical Devices and Eye Drops	Texas
3040335	Bridgewater Biologics Botox R&D	New Jersey
1058672	Davie Generic Solid Dose Tablets & Capsules	Florida
3081567	Blue Ash Branded Pharmaceutical Packaging and Testing*	Ohio
	*under construction

Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, three offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle™, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities.